Zacks.com on MSN23h
IONS’ Better-Than-Expected Q4 Results
EC approves MRK's Welireg for two indications. FDA grants priority review to SNY and REGN's Dupixent sBLA for bullous pemphigoid.
Healio16h
Families ‘thrilled’ with omalizumab in the year since its approval for food allergy
As we approach the first anniversary of omalizumab’s approval for food allergy, its use is “definitely going to grow,” Robert ...